✨ Medicines Consent Notices




11 MARCH

NEW ZEALAND GAZETTE

613

Product:
Sonaflam

Active Ingredient:
Naproxen sodium 275mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Multichem NZ Limited

Manufacturer:
Cipla Limited, Patalganga Industrial Area, District Raigad (Maharashtra), India

Dated this 4th day of March 2004.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).

go1567

Renewal of Provisional Consent to the Distribution of New Medicines

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product:
Arava

Active Ingredient:
Leflunomide 10mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Aventis Pharma Limited

Manufacturer:
Usiphar, Compeigne, France

Note: This consent is valid for two years from 23 March 2004.

Product:
Arava

Active Ingredient:
Leflunomide 100mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Aventis Pharma Limited

Manufacturer:
Usiphar, Compeigne, France

Note: This consent is valid for two years from 23 March 2004.

Product:
Arava

Active Ingredient:
Leflunomide 20mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Aventis Pharma Limited

Manufacturer:
Usiphar, Compeigne, France

Note: This consent is valid for two years from 23 March 2004.

Product:
Codalax Forte

Active Ingredients:
Danthron 15mg/mL
Poloxamer 188 200mg/mL

Dosage Form:
Oral suspension

New Zealand Sponsor:
Douglas Pharmaceuticals Limited

Manufacturer:
Douglas Pharmaceuticals Limited, Lincoln, Auckland

This consent is given subject to the following condition:

● This medicine may only be used for the prevention or treatment of constipation in the terminally ill.

Note: This consent is valid for two years from 30 July 2004.

Product:
Codalax

Active Ingredients:
Danthron 5mg/mL
Poloxamer 188 40mg/mL

Dosage Form:
Oral suspension

New Zealand Sponsor:
Douglas Pharmaceuticals Limited

Manufacturer:
Douglas Pharmaceuticals Limited, Lincoln, Auckland

This consent is given subject to the following condition:

● This medicine may only be used for the prevention or treatment of constipation in the terminally ill.

Note: This consent is valid for two years from 30 July 2004.

Product:
Pentaspan

Active Ingredient:
Poly-O-(2-hydroxyethyl)-starch 100mg/mL

Dosage Form:
Solution for infusion

New Zealand Sponsor:
Boots Healthcare New Zealand Limited

Manufacturer:
NPBI BV, Emmer-Compascuum, The Netherlands

Note: This consent is valid for two years from 20 April 2004.

Dated this 4th day of March 2004.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).

go1566



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2004, No 26


Gazette.govt.nz PDF NZ Gazette 2004, No 26





✨ LLM interpretation of page content

πŸ₯ Provisional Consent for Sonaflam Distribution

πŸ₯ Health & Social Welfare
4 March 2004
Medicines, Distribution, Sonaflam, Naproxen sodium
  • DON MATHESON, Deputy Director-General, Public Health

πŸ₯ Renewal of Provisional Consent for New Medicines

πŸ₯ Health & Social Welfare
4 March 2004
Medicines, Distribution, Arava, Codalax, Pentaspan
  • DON MATHESON, Deputy Director-General, Public Health